Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
数码之外：4位分析师讨论Entrada Therapeutics股票
Exploring Analyst...In the preceding three months, 4 analysts have released ratings for Entrada Therapeutics (NASDAQ:TRDA), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，4位分析师发布了对Entrada Therapeutics（纳斯达克：TRDA）的评级，呈现了从看好到看淡的各种观点。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析师最近的评级概述，为了全面了解过去30天的情绪变化并与前几个月进行比较，提供了深入的见解。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $28.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $21.50.
分析师评估的12个月价目标揭示了进一步的见解，平均目标为22.75美元，最高估值为28.00美元，最低估值为18.00美元。目前的平均价目标已经较之前的21.50美元的目标上涨了5.81％，显示出积极的变化。
Exploring Analyst...
分析...
登录免费看全文
登录/注册
资讯热榜
更新时间